{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:28:50Z","timestamp":1790087330820,"version":"4.0.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2016,5,10]],"date-time":"2016-05-10T00:00:00Z","timestamp":1462838400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammation"],"DOI":"10.1007\/s10753-016-0359-6","type":"journal-article","created":{"date-parts":[[2016,5,10]],"date-time":"2016-05-10T05:13:59Z","timestamp":1462857239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy"],"prefix":"10.1007","author":[{"given":"Luigi","family":"Di Luigi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Corinaldesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Colletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Scolletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Antinozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella B.","family":"Vannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Giannetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Gianfrilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Isidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Migliaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Poerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Fraziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Crescioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,10]]},"reference":[{"key":"359_CR1","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/01.RES.0000043825.01705.1B","volume":"91","author":"DL Mann","year":"2002","unstructured":"Mann, D.L. 2002. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circulation Research 91: 988\u201398. doi: 10.1161\/01.RES.0000043825.01705.1B .","journal-title":"Circulation Research"},{"key":"359_CR2","doi-asserted-by":"crossref","first-page":"847827","DOI":"10.1155\/2014\/847827","volume":"2014","author":"J Fuentes-Antr\u00e1s","year":"2014","unstructured":"Fuentes-Antr\u00e1s, J., A.M. Ioan, J. Tu\u00f1\u00f3n, J. Egido, and \u00d3. Lorenzo. 2014. Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation. International Journal of Endocrinology 2014: 847827. doi: 10.1155\/2014\/847827 .","journal-title":"International Journal of Endocrinology"},{"key":"359_CR3","doi-asserted-by":"crossref","unstructured":"Esser, N., S. Legrand-Poels, J. Piette, A.J. Scheen, and N. Paquot. 2014. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Research and Clinical Practice 105:141\u201350. doi: 10.1016\/j.diabres.2014.04.006 .","DOI":"10.1016\/j.diabres.2014.04.006"},{"key":"359_CR4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bcp.2009.04.029","volume":"78","author":"AH Sprague","year":"2009","unstructured":"Sprague, A.H., and R.A. Khalil. 2009. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochemical Pharmacology 78: 539\u201352. doi: 10.1016\/j.bcp.2009.04.029 .","journal-title":"Biochemical Pharmacology"},{"key":"359_CR5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000338166","volume":"122","author":"L Gullestad","year":"2012","unstructured":"Gullestad, L., T. Ueland, L.E. Vinge, A. Finsen, A. Yndestad, and P. Aukrust. 2012. Inflammatory cytokines in heart failure: mediators and markers. Cardiology 122: 23\u201335. doi: 10.1159\/000338166 .","journal-title":"Cardiology"},{"key":"359_CR6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1042\/CS20040174","volume":"108","author":"S Kofler","year":"2005","unstructured":"Kofler, S., T. Nickel, and M. Weis. 2005. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clinical Science (London) 108: 205\u201313. doi: 10.1042\/CS20040174 .","journal-title":"Clinical Science (London)"},{"key":"359_CR7","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2337\/diacare.27.3.813","volume":"27","author":"JC Pickup","year":"2004","unstructured":"Pickup, J.C. 2004. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27: 813\u201323. doi: 10.2337\/diacare.27.3.813 .","journal-title":"Diabetes Care"},{"key":"359_CR8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/CS20130497","volume":"126","author":"I Striz","year":"2014","unstructured":"Striz, I., E. Brabcova, L. Kolesar, and A. Sekerkova. 2014. Cytokine networking of innate immunity cells: a potential target of therapy. Clinical Science (London) 126: 593\u2013612. doi: 10.1042\/CS20130497 .","journal-title":"Clinical Science (London)"},{"key":"359_CR9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/cvr\/cvp241","volume":"84","author":"S Apostolakis","year":"2009","unstructured":"Apostolakis, S., K. Vogiatzi, V. Amanatidou, and D.A. Spandidos. 2009. Interleukin 8 and cardiovascular disease. Cardiovascular Research 84: 353\u201360. doi: 10.1093\/cvr\/cvp241 .","journal-title":"Cardiovascular Research"},{"key":"359_CR10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/cvr\/cvq083","volume":"86","author":"F Sanchez-Madrid","year":"2010","unstructured":"Sanchez-Madrid, F., and W.C. Sessa. 2010. Spotlight on mechanisms of vascular inflammation. Cardiovascular Research 86: 171\u20133. doi: 10.1093\/cvr\/cvq083 .","journal-title":"Cardiovascular Research"},{"key":"359_CR11","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1189\/jlb.0405182","volume":"78","author":"VC Mehra","year":"2005","unstructured":"Mehra, V.C., V.S. Ramgolam, and J.R. Bender. 2005. Cytokines and cardiovascular disease. Journal of Leukocyte Biology 78: 805\u201318. doi: 10.1189\/jlb.0405182 .","journal-title":"Journal of Leukocyte Biology"},{"key":"359_CR12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/TP.0b013e3181919f5d","volume":"87","author":"C Crescioli","year":"2009","unstructured":"Crescioli, C., A. Buonamano, S. Scolletta, M. Sottili, M. Francalanci, P. Giomarelli, et al. 2009. Predictive role of pretransplant serum CXCL10 for cardiac acute rejection. Transplantation 87: 249\u201355. doi: 10.1097\/TP.0b013e3181919f5d .","journal-title":"Transplantation"},{"key":"359_CR13","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.cca.2012.02.009","volume":"413","author":"P Romagnani","year":"2012","unstructured":"Romagnani, P., and C. Crescioli. 2012. CXCL10: a candidate biomarker in transplantation. Clinica Chimica Acta 413: 1364\u201373. doi: 10.1016\/j.cca.2012.02.009 .","journal-title":"Clinica Chimica Acta"},{"key":"359_CR14","first-page":"893106","volume":"2014","author":"P Borne van den","year":"2014","unstructured":"van den Borne, P., P.H. Quax, I.E. Hoefer, and G. Pasterkamp. 2014. The multifaceted functions of CXCL10 in cardiovascular disease. Biomedical Research International 2014: 893106. doi: 10.1155\/2014\/893106 .","journal-title":"Biomedical Research International"},{"key":"359_CR15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.biomag.2011.07.001","volume":"2","author":"S Scolletta","year":"2012","unstructured":"Scolletta, S., A. Buonamano, M. Sottili, P. Giomarelli, B. Biagioli, G.B. Vannelli, et al. 2012. CXCL10 release in cardiopulmonary bypass: an in vivo and in vitro study. Biomedicine and Aging Pathology 2: 187\u201394. doi: 10.1016\/j.biomag.2011.07.001 .","journal-title":"Biomedicine and Aging Pathology"},{"key":"359_CR16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1096\/fj.02-0908fje","volume":"18","author":"JD Campbell","year":"2004","unstructured":"Campbell, J.D., V. Gangur, F.E. Simons, and K.T. HayGlass. 2004. Allergic humans are hyporesponsive to a CXCR3-ligand-mediated Th1 immunity-promoting loop. FASEB 18: 329\u201331. doi: 10.1096\/fj.02-0908fje .","journal-title":"FASEB"},{"key":"359_CR17","doi-asserted-by":"crossref","first-page":"e18186","DOI":"10.1371\/journal.pone.0018186","volume":"6","author":"Y Yue","year":"2011","unstructured":"Yue, Y., J. Gui, W. Ai, W. Xu, and S. Xiong. 2011. Direct gene transfer with IP-10 mutant ameliorates mouse CVB3-induced myocarditis by blunting Th1 immune responses. PLoS One 6: e18186. doi: 10.1371\/journal.pone.0018186 .","journal-title":"PLoS One"},{"key":"359_CR18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejcb.2011.09.011","volume":"91","author":"C Crescioli","year":"2012","unstructured":"Crescioli, C., M. Sottili, P. Bonini, L. Cosmi, P. Chiarugi, P. Romagnani, et al. 2012. Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target. European Journal of Cell Biology 91: 139\u201349. doi: 10.1016\/j.ejcb.2011.09.011 .","journal-title":"European Journal of Cell Biology"},{"key":"359_CR19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1677\/JOE-07-0240","volume":"195","author":"C Crescioli","year":"2007","unstructured":"Crescioli, C., L. Cosmi, E. Borgogni, V. Santarlasci, S. Gelmini, M. Sottili, et al. 2007. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. Journal of Endocrinology 195: 145\u201355. doi: 10.1677\/JOE-07-0240 .","journal-title":"Journal of Endocrinology"},{"key":"359_CR20","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.yexcr.2007.12.016","volume":"314","author":"C Crescioli","year":"2008","unstructured":"Crescioli, C., R. Squecco, L. Cosmi, M. Sottili, S. Gelmini, E. Borgogni, et al. 2008. Immunosuppression in cardiac graft rejection: a human in vitro model to study the potential use of new immunomodulatory drugs. Experimental Cell Research 314: 1337\u201350. doi: 10.1016\/j.yexcr.2007.12.016 .","journal-title":"Experimental Cell Research"},{"key":"359_CR21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.expneurol.2013.10.021","volume":"251","author":"P Pifarr\u00e9","year":"2014","unstructured":"Pifarr\u00e9, P., M. Gutierrez-Mecinas, J. Prado, L. Usero, C. Roura-Mir, M. Giralt, et al. 2014. Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions. Experimental Neurology 251: 58\u201371. doi: 10.1016\/j.expneurol.2013.10.021 .","journal-title":"Experimental Neurology"},{"key":"359_CR22","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1096\/fj.00-0538com","volume":"15","author":"H Senzaki","year":"2001","unstructured":"Senzaki, H., C.J. Smith, G.J. Juang, T. Isoda, A. Ohler, N. Paolocci, et al. 2001. Cardiac phosphodiesterase 5 (cGMP specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB Journal 15: 1718\u201326. doi: 10.1096\/fj.00-0538com .","journal-title":"FASEB Journal"},{"key":"359_CR23","doi-asserted-by":"crossref","first-page":"12944","DOI":"10.1074\/jbc.M404706200","volume":"280","author":"A Das","year":"2005","unstructured":"Das, A., L. Xi, and R.C. Kukreja. 2005. Phosphodiesterase-5 inhibitor, sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis: essential role of NO signaling. Journal of Biological Chemistry 280: 12944\u201355. doi: 10.1074\/jbc.M404706200 .","journal-title":"Journal of Biological Chemistry"},{"key":"359_CR24","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.bjp.0707132","volume":"150","author":"RC Kukreja","year":"2007","unstructured":"Kukreja, R.C. 2007. Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. British Journal of Pharmacology 150: 538\u201340. doi: 10.1038\/sj.bjp.0707132 .","journal-title":"British Journal of Pharmacology"},{"key":"359_CR25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.bjp.0707131","volume":"150","author":"G Rossoni","year":"2007","unstructured":"Rossoni, G., B. Manfredi, Colonna V. De Gennaro, M. Berti, M. Guazzi, and F. Berti. 2007. Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. British Journal of Pharmacology 150: 567\u201376. doi: 10.1038\/sj.bjp.0707131 .","journal-title":"British Journal of Pharmacology"},{"key":"359_CR26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pestbp.2006.08.007","volume":"87","author":"GR Zahra","year":"2007","unstructured":"Zahra, G.R., D.F. Elham, A. Atousa, E. Hadi, M. Azadeh, N.O. Seyed, and A. Mohammad. 2007. Protection by cAMP and cGMP phosphodiesterase inhibitors of diazinon-induced hyperglycemia and oxidative\/nitrosative stress in rat Langerhans islets cells: molecular evidence for involvement of non-cholinergic mechanisms. Pesticide Biochemistry and Physiology 87: 261\u201370. doi: 10.1016\/j.pestbp.2006.08.007 .","journal-title":"Pesticide Biochemistry and Physiology"},{"key":"359_CR27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4239\/wjd.v1.i1.3","volume":"1","author":"A Aversa","year":"2010","unstructured":"Aversa, A. 2010. Systemic and metabolic effects of PDE5-inhibitor drugs. World Journal of Diabetes 1: 3\u20137. doi: 10.4239\/wjd.v1.i1.3 .","journal-title":"World Journal of Diabetes"},{"key":"359_CR28","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/sj.bjp.0707409","volume":"152","author":"DS Burley","year":"2007","unstructured":"Burley, D.S., P. Ferdinandy, and G.F. Baxter. 2007. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. British Journal of Pharmacology 152: 855\u201369. doi: 10.1038\/sj.bjp.0707409 .","journal-title":"British Journal of Pharmacology"},{"key":"359_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/aps.2008.1","volume":"30","author":"YJ Rao","year":"2009","unstructured":"Rao, Y.J., and L. Xi. 2009. Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Acta Pharmacologica Sinica 30: 1\u201324. doi: 10.1038\/aps.2008.1 .","journal-title":"Acta Pharmacologica Sinica"},{"key":"359_CR30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCHEARTFAILURE.110.944694","volume":"4","author":"M Guazzi","year":"2011","unstructured":"Guazzi, M., M. Vicenzi, R. Arena, and M.D. Guazzi. 2011. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circulation. Heart Failure 4: 8\u201317. doi: 10.1161\/CIRCHEARTFAILURE.110.944694 .","journal-title":"Circulation. Heart Failure"},{"key":"359_CR31","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/CIRCULATIONAHA.111.063412","volume":"125","author":"E Giannetta","year":"2012","unstructured":"Giannetta, E., A.M. Isidori, N. Galea, I. Carbone, E. Mandosi, C.D. Vizza, et al. 2012. Chronic inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 125: 2323\u201333. doi: 10.1161\/CIRCULATIONAHA.111.063412 .","journal-title":"Circulation"},{"key":"359_CR32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yjmcc.2003.11.001","volume":"36","author":"RC Kukreja","year":"2004","unstructured":"Kukreja, R.C., R. Ockaili, F. Salloum, C. Yin, J. Hawkins, A. Das, and L. Xi. 2004. Cardioprotection with phosphodiesterase-5 inhibition-a novel preconditioning strategy. Journal of Molecular and Cellular Cardiology 36: 165\u201373. doi: 10.1016\/j.yjmcc.2003.11.001 .","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"359_CR33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1124\/mol.104.004853","volume":"67","author":"SJ Netherton","year":"2005","unstructured":"Netherton, S.J., and D.H. Maurice. 2005. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Molecular Pharmacology 67: 263\u201372. doi: 10.1124\/mol.104.004853 .","journal-title":"Molecular Pharmacology"},{"key":"359_CR34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/cvr\/cvq410","volume":"90","author":"MA Gebska","year":"2011","unstructured":"Gebska, M.A., B.K. Stevenson, A.R. Hemnes, T.J. Bivalacqua, A. Haile, G.G. Hesketh, et al. 2011. Phosphodiesterase-5A (PDE5A) is localized to the endothelial caveolae and modulates NOS3 activity. Cardiovascular Research 90: 353\u201363. doi: 10.1093\/cvr\/cvq410 .","journal-title":"Cardiovascular Research"},{"issue":"19 Suppl 3","key":"359_CR35","first-page":"III352","volume":"102","author":"EJ Birks","year":"2000","unstructured":"Birks, E.J., P.B. Burton, V. Owen, A.J. Mullen, D. Hunt, N.R. Banner, et al. 2000. Elevated tumor necrosis factor-alpha and interleukin-6 in myocardium and serum of malfunctioning donor hearts. Circulation 102(19 Suppl 3): III352\u20138.","journal-title":"Circulation"},{"key":"359_CR36","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00011-004-1298-5","volume":"53","author":"NG Frangogiannis","year":"2004","unstructured":"Frangogiannis, N.G. 2004. Chemokines in the ischemic myocardium: from inflammation to fibrosis. Inflammation Research 53: 585\u201395.","journal-title":"Inflammation Research"},{"key":"359_CR37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0735-1097(00)00790-7","volume":"36","author":"SD Katz","year":"2000","unstructured":"Katz, S.D., K. Balidemaj, S. Homma, H. Wu, J. Wang, and S. Maybaum. 2000. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. Journal of the American College of Cardiology 36: 845\u201351. doi: 10.1016\/S0735-1097(00)00790-7 .","journal-title":"Journal of the American College of Cardiology"},{"key":"359_CR38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.yexcr.2008.10.025","volume":"315","author":"M Sottili","year":"2009","unstructured":"Sottili, M., L. Cosmi, E. Borgogni, E. Sarchielli, L. Maggi, M. Francalanci, et al. 2009. Immunomodulatory effects of BXL-01-0029, a less hypercalcemic vitamin D analogue, in human cardiomyocytes and T cells. Experimental Cell Research 315: 264\u201373. doi: 10.1016\/j.yexcr.2008.10.025 .","journal-title":"Experimental Cell Research"},{"key":"359_CR39","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/CIRCRESAHA.107.162511","volume":"101","author":"DA Kass","year":"2007","unstructured":"Kass, D.A., H.C. Champion, and J.A. Beavo. 2007. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circulation Research 101: 1084\u201395. doi: 10.1161\/CIRCRESAHA.107.162511 .","journal-title":"Circulation Research"},{"key":"359_CR40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11897-012-0101-0","volume":"9","author":"DA Kass","year":"2012","unstructured":"Kass, D.A. 2012. Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. Current Heart Failure Reports 9: 192\u201399. doi: 10.1007\/s11897-012-0101-0 .","journal-title":"Current Heart Failure Reports"},{"key":"359_CR41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1203\/01.PDR.0000147736.27672.15","volume":"57","author":"YA Bremer","year":"2005","unstructured":"Bremer, Y.A., F. Salloum, R. Ockaili, E. Chou, W.B. Moskowitz, and R.C. Kukreja. 2005. Sildenafil citrate (Viagra) induces cardioprotective effects after ischemia\/reperfusion injury in infant rabbits. Pediatric Research 57: 22\u20137. doi: 10.1203\/01.PDR.0000147736.27672.15 .","journal-title":"Pediatric Research"},{"key":"359_CR42","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.bjp.0705658","volume":"141","author":"O Nagy","year":"2004","unstructured":"Nagy, O., A. Hajnal, J.R. Parratt, and V. Agnes. 2004. Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs. British Journal of Pharmacology 141: 549\u201351. doi: 10.1038\/sj.bjp.0705658 .","journal-title":"British Journal of Pharmacology"},{"key":"359_CR43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.yjmcc.2006.10.015","volume":"42","author":"FN Salloum","year":"2007","unstructured":"Salloum, F.N., Y. Takenoshita, R.A. Ockaili, V.P. Daoud, E. Chou, K. Yoshida, and R.C. Kukreja. 2007. Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. Journal of Molecular and Cellular Cardiology 42: 453\u20138. doi: 10.1016\/j.yjmcc.2006.10.015 .","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"359_CR44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40618-015-0340-5","volume":"39","author":"C Corinaldesi","year":"2016","unstructured":"Corinaldesi, C., L. Di Luigi, A. Lenzi, and C. Crescioli. 2016. Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications. Journal of Endocrinological Investigation 39: 143\u201351. doi: 10.1007\/s40618-015-0340-5 .","journal-title":"Journal of Endocrinological Investigation"},{"key":"359_CR45","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0006-291X(90)92168-Y","volume":"170","author":"LJ Ignarro","year":"1990","unstructured":"Ignarro, L.J., P.A. Bush, G.M. Buga, K.S. Wood, J.M. Fukuto, and J. Rajfer. 1990. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochemical and Biophysical Research Communications 170: 843\u201350. doi: 10.1016\/0006-291X(90)92168-Y .","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"359_CR46","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJM199201093260203","volume":"326","author":"J Rajfer","year":"1992","unstructured":"Rajfer, J., W.J. Aronson, P.A. Bush, F.J. Dorey, and L.J. Ignarro. 1992. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. New England Journal of Medicine 326: 90\u201394. doi: 10.1056\/NEJM199201093260203 .","journal-title":"New England Journal of Medicine"},{"key":"359_CR47","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.vph.2005.02.010","volume":"42","author":"RC Kukreja","year":"2005","unstructured":"Kukreja, R.C., F. Salloum, A. Das, R. Ockaili, C. Yin, Y.A. Bremer, et al. 2005. Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. Vascular Pharmacology 42: 219\u201332. doi: 10.1016\/j.vph.2005.02.010 .","journal-title":"Vascular Pharmacology"},{"key":"359_CR48","first-page":"e30","volume":"16","author":"RC Kukreja","year":"2011","unstructured":"Kukreja, R.C., F.N. Salloum, A. Das, S. Koka, R.A. Ockaili, and L. Xi. 2011. Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. Experimental and Clinical Cardiology 16: e30\u20135.","journal-title":"Experimental and Clinical Cardiology"},{"key":"359_CR49","doi-asserted-by":"crossref","first-page":"e104890","DOI":"10.1371\/journal.pone.0104890","volume":"9","author":"T Kiss","year":"2014","unstructured":"Kiss, T., K. Kovacs, A. Komocsi, A. Tornyos, P. Zalan, B. Sumegi, et al. 2014. Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines\/chemokines. MAP kinases and Akt. PLoS One 9: e104890. doi: 10.1371\/journal.pone.0104890 .","journal-title":"PLoS One"},{"key":"359_CR50","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.bbrc.2004.11.153","volume":"327","author":"E Vellaichamy","year":"2005","unstructured":"Vellaichamy, E., N.K. Sommana, and K.N. Pandey. 2005. Reduced cGMP signaling activates NF-kappaB in hypertrophied hearts of mice lacking natriuretic peptide receptor-A. Biochemical and Biophysical Research Communications 327: 106\u201311. doi: 10.1016\/j.bbadis.2009.09.009 .","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"359_CR51","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/01.ATV.18.11.1796","volume":"18","author":"K Katsuyama","year":"1998","unstructured":"Katsuyama, K., M. Shichiri, F. Marumo, and Y. Hirata. 1998. NO inhibits cytokine-induced iNOS expression and NF-kappaB activation by interfering with phosphorylation and degradation of IkappaB-alpha. Arteriosclerosis, Thrombosis, and Vascular Biology 18: 1796\u2013802. doi: 10.1161\/01.ATV.18.11.1796 .","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"359_CR52","doi-asserted-by":"crossref","first-page":"15328","DOI":"10.1074\/jbc.M114.547349","volume":"289","author":"DP Harris","year":"2014","unstructured":"Harris, D.P., S. Bandyopadhyay, T.J. Maxwell, B. Willard, and P.E. Di Corleto. 2014. Tumor necrosis factor (TNF)-\u03b1 induction of CXCL10 in endothelial cells requires protein arginine methyltransferase 5 (PRMT5)-mediated nuclear factor (NF)-\u03baB p65 methylation. Journal of Biological Chemistry 289: 15328\u201339. doi: 10.1074\/jbc.M114.547349 .","journal-title":"Journal of Biological Chemistry"},{"key":"359_CR53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/gb-2003-4-9-117","volume":"4","author":"D Greenbaum","year":"2014","unstructured":"Greenbaum, D., C. Colangelo, K. Williams, and M. Gerstein. 2014. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biology 4: 117. doi: 10.1186\/gb-2003-4-9-117 .","journal-title":"Genome Biology"},{"key":"359_CR54","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.147.11.3815","volume":"11","author":"DF Fiorentino","year":"1991","unstructured":"Fiorentino, D.F., A. Zlotnik, T.R. Mosmann, M. Howard, and A. O\u2019Garra. 1991. IL-10 inhibits cytokine production by activated macrophages. Journal of Immunology 11: 3815. doi: 10.1159\/000346707 .","journal-title":"Journal of Immunology"},{"key":"359_CR55","doi-asserted-by":"crossref","first-page":"23301","DOI":"10.1016\/S0021-9258(18)50091-0","volume":"267","author":"C Bogdan","year":"1992","unstructured":"Bogdan, C., J. Paik, Y. Vodovotz, and C. Nathan. 1992. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-\u03b2 and interleukin-10. Journal of Biological Chemistry 267: 23301.","journal-title":"Journal of Biological Chemistry"},{"key":"359_CR56","doi-asserted-by":"crossref","first-page":"811","DOI":"10.4049\/jimmunol.153.2.811","volume":"153","author":"P Wang","year":"1994","unstructured":"Wang, P., P. Wu, M.I. Siegel, R.W. Egan, and M.M. Billah. 1994. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. Journal of Immunology 153: 811.","journal-title":"Journal of Immunology"},{"key":"359_CR57","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.4049\/jimmunol.155.3.1489","volume":"155","author":"P Shrikant","year":"1995","unstructured":"Shrikant, P., E. Weber, T. Jilling, and E.N. Benveniste. 1995. Intercellular adhesion molecule-1 gene expression by glial cells. Differential mechanisms of inhibition by IL-10 and IL-6. Journal of Immunology 155: 1489.","journal-title":"Journal of Immunology"},{"key":"359_CR58","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.4049\/jimmunol.155.9.4412","volume":"155","author":"N Berkman","year":"1995","unstructured":"Berkman, N., M. John, G. Roesems, P.J. Jose, P.J. Barnes, and K.F. Chung. 1995. Inhibition of macrophage inflammatory protein-1\u03b1 expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages. Journal of Immunology 155: 4412. doi: 10.1124\/jpet.111.180737 .","journal-title":"Journal of Immunology"},{"key":"359_CR59","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.4049\/jimmunol.156.7.2591","volume":"156","author":"S Takeshita","year":"1996","unstructured":"Takeshita, S., J.R. Gage, T. Kishimoto, D.L. Vredevoe, and O. Mart\u0131\u0301nez-Maza. 1996. Differential regulation of IL-6 gene transcription and expression by IL-4 and IL-10 in human monocytic cell lines. Journal of Immunology 156: 2591.","journal-title":"Journal of Immunology"},{"key":"359_CR60","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1182\/blood.V89.12.4461","volume":"89","author":"S Song","year":"1997","unstructured":"Song, S., H. Ling-Hu, K.A. Roebuck, M.F. Rabbi, R.P. Donnelly, and A. Finnegan. 1997. Interleukin-10 inhibits interferon-\u03b3\u2013induced intercellular adhesion molecule-1 gene transcription in human monocytes. Blood 89: 4461.","journal-title":"Blood"},{"key":"359_CR61","doi-asserted-by":"crossref","first-page":"20108","DOI":"10.1074\/jbc.271.33.20108","volume":"271","author":"CY Brown","year":"1996","unstructured":"Brown, C.Y., C.A. Lagnado, M.A. Vadas, and G.J. Goodall. 1996. Differential regulation of the stability of cytokine mRNAs in lipopolysaccharide-activated blood monocytes in response to interleukin-10. Journal of Biological Chemistry 271: 20108. doi: 10.1074\/jbc.271.33.20108 .","journal-title":"Journal of Biological Chemistry"},{"key":"359_CR62","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.178.1.63","volume":"178","author":"T Kasama","year":"1993","unstructured":"Kasama, T., R.M. Strieter, T.J. Standiford, M.D. Burdick, and S.L. Kunkel. 1993. Expression and regulation of human neutrophil-derived macrophage inflammatory protein 1\u03b1. Journal of Experimental Medicine 178: 63.","journal-title":"Journal of Experimental Medicine"},{"key":"359_CR63","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1182\/blood.V92.12.4742","volume":"92","author":"JM Tebo","year":"1998","unstructured":"Tebo, J.M., H.S. Kim, J. Gao, D.A. Armstrong, and T.A. Hamilton. 1998. Interleukin-10 suppresses IP-10 gene transcription by inhibiting the production of class I interferon. Blood 92: 4742\u20134749. doi: 10.1182\/blood-2013-03-490961 .","journal-title":"Blood"},{"key":"359_CR64","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cytogfr.2014.01.006","volume":"25","author":"A Antonelli","year":"2014","unstructured":"Antonelli, A., S.M. Ferrari, A. Corrado, E. Ferrannini, and P. Fallahi. 2014. CXCR3, CXCL10 and type 1 diabetes. Cytokine and Growth Factor Reviews 25: 57\u201365. doi: 10.1016\/j.cytogfr.2014.01.006 .","journal-title":"Cytokine and Growth Factor Reviews"},{"key":"359_CR65","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijcard.2014.01.102","volume":"172","author":"XD Zhuang","year":"2014","unstructured":"Zhuang, X.D., M. Long, F. Li, X. Hu, X.X. Liao, and Z.M. Du. 2014. PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials. International Journal of Cardiology 172: 581\u201387. doi: 10.1016\/j.ijcard.2014.01.102 .","journal-title":"International Journal of Cardiology"},{"key":"359_CR66","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1161\/CIRCHEARTFAILURE.112.969071","volume":"5","author":"MM Redfield","year":"2012","unstructured":"Redfield, M.M., B.A. Borlaug, G.D. Lewis, S.F. Mohammed, M.J. Semigran, M.M. Lewinter, et al. 2012. Heart Failure Clinical Research Network. PhosphdiesteRasE-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial: rationale and design. Circulation. Heart Failure 5: 653\u20139. doi: 10.1161\/CIRCHEARTFAILURE.112.96907 .","journal-title":"Circulation. Heart Failure"},{"key":"359_CR67","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","volume":"309","author":"MM Redfield","year":"2013","unstructured":"Redfield, M.M., H.H. Chen, B.A. Borlaug, M.J. Semigran, K.L. Lee, G. Lewis, et al. 2013. RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309: 1268\u20131277. doi: 10.1001\/jama.2013.2024 .","journal-title":"JAMA"},{"key":"359_CR68","doi-asserted-by":"crossref","first-page":"e0118664","DOI":"10.1371\/journal.pone.0118664","volume":"10","author":"CV Degen","year":"2015","unstructured":"Degen, C.V., K. Bishu, R. Zakeri, O. Ogut, M.M. Redfield, and F.V. Brozovich. 2015. The emperor\u2019s new clothes: PDE5 and the heart. PLoS One 10: e0118664. doi: 10.1371\/journal.pone.0118664 .","journal-title":"PLoS One"},{"key":"359_CR69","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1161\/CIRCULATIONAHA.112.000056","volume":"127","author":"MJ Andersen","year":"2013","unstructured":"Andersen, M.J., M. Ersb\u00f8ll, A. Axelsson, F. Gustafsson, C. Hassager, L. Kober, et al. 2013. Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the sildenafil and diastolic dysfunction after acute myocardial infarction (SIDAMI) trial. Circulation 127: 1200\u201308. doi: 10.1161\/CIRCULATIONAHA.112.000056 .","journal-title":"Circulation"},{"key":"359_CR70","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nm1175","volume":"11","author":"E Takimoto","year":"2005","unstructured":"Takimoto, E., H.C. Champion, M. Li, D. Belardi, S. Ren, E.R. Rodriguez, et al. 2005. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nature Medicine 11: 214\u201322.","journal-title":"Nature Medicine"},{"key":"359_CR71","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/CIRCULATIONAHA.106.655266","volume":"116","author":"J Nagendran","year":"2007","unstructured":"Nagendran, J., S.L. Archer, D. Soliman, V. Gurtu, R. Moudgil, A. Haromy, et al. 2007. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116: 238\u201348. doi: 10.1038\/nm1175 .","journal-title":"Circulation"},{"key":"359_CR72","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1161\/CIRCHEARTFAILURE.111.961706","volume":"5","author":"X Shan","year":"2012","unstructured":"Shan, X., M.P. Quaile, J.K. Monk, B. French, T.P. Cappola, and K.B. Margulies. 2012. Differential expression of PDE5 in failing and nonfailing human myocardium. Circulation. Heart Failure 5: 79\u201386. doi: 10.1161\/CIRCHEARTFAILURE.111.961706 .","journal-title":"Circulation. Heart Failure"},{"key":"359_CR73","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/CIRCULATIONAHA.108.822072","volume":"119","author":"P Pokreisz","year":"2009","unstructured":"Pokreisz, P., S. Vandenwijngaert, V. Bito, A. Van den Bergh, I. Lenaerts, C. Busch, et al. 2009. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 119: 408\u201316. doi: 10.1161\/CIRCULATIONAHA.108.822072 .","journal-title":"Circulation"},{"key":"359_CR74","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1161\/CIRCULATIONAHA.109.906818","volume":"121","author":"Z Lu","year":"2010","unstructured":"Lu, Z., X. Xu, X. Hu, S. Lee, J.H. Traverse, G. Zhu, J. Fassett, et al. 2010. Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation 121: 1474\u201383. doi: 10.1161\/CIRCULATIONAHA.109.906818 .","journal-title":"Circulation"},{"key":"359_CR75","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","volume":"32","author":"BA Borlaug","year":"2011","unstructured":"Borlaug, B.A., and W.J. Paulus. 2011. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. European Heart Journal 32: 670\u20139. doi: 10.1093\/eurheartj\/ehq426 .","journal-title":"European Heart Journal"},{"key":"359_CR76","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","volume":"353","author":"N Galie","year":"2005","unstructured":"Galie, N., H.A. Ghofrani, A. Torbicki, R.J. Barst, L.J. Rubin, D. Badesch, et al. 2005. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine 353: 2148\u201357. doi: 10.1056\/NEJMoa050010 .","journal-title":"New England Journal of Medicine"},{"key":"359_CR77","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/cvr\/cvu030","volume":"102","author":"A Ghigo","year":"2014","unstructured":"Ghigo, A., I. Franco, F. Morello, and E. Hirsch. 2014. Myocyte signalling in leucocyte recruitment to the heart. Cardiovascular Research 102: 270\u201380. doi: 10.1093\/cvr\/cvu030 .","journal-title":"Cardiovascular Research"},{"key":"359_CR78","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cyto.2014.12.024","volume":"74","author":"JA Fontes","year":"2015","unstructured":"Fontes, J.A., N.R. Rose, and D. \u010cih\u00e1kov\u00e1. 2015. The varying faces of IL-6: From cardiac protection to cardiac failure. Cytokine 74: 62\u20138. doi: 10.1016\/j.cyto.2014.12.024 .","journal-title":"Cytokine"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-016-0359-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10753-016-0359-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-016-0359-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T08:55:22Z","timestamp":1718528122000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10753-016-0359-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,10]]},"references-count":78,"alternative-id":["359"],"URL":"https:\/\/doi.org\/10.1007\/s10753-016-0359-6","relation":{},"ISSN":["0360-3997","1573-2576"],"issn-type":[{"value":"0360-3997","type":"print"},{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,10]]}}}